Navigation Links
Omeros Corporation Reports Second Quarter 2013 Financial Results
Date:8/9/2013

SEATTLE, Aug. 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

Financial ResultsTotal operating expenses for the quarter ended June 30, 2013 were $13.3 million and included non-cash expenses of $2.1 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $9.8 million, which included non-cash rent and stock-based compensation expenses of $569,000.

The increase in total operating expenses for the quarter ended June 30, 2013 is primarily due to expenses related to advancing our MASP-2 program toward the clinic, the non-cash rent expense and stock-based compensation discussed above, preparing the NDA and MAA for OMS302, the planned commercial launch of OMS302 in 2014, and conducting our Phase 1 clinical program evaluating OMS824. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of our OMS302 Phase 3 clinical program in January 2013 and the completion of our first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended June 30, 2013 was $140,000 compared to $1.5 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended June 30, 2013, O
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
2. Omeros Submits New Drug Application to U.S. FDA for OMS302
3. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
4. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
5. Omeros Corporation Reports First Quarter 2013 Financial Results
6. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
7. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
8. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
9. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
10. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
11. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
(Date:7/24/2014)... July 24, 2014 Talyst, a market leader ... National Association of State Veterans Homes (NASVH) Summer Conference ... goal of the NASVH is to ensure that each ... long term health care and respect which they have ... With the InSite® Remote Dispensing System, Talyst can help ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... N.Y., Sept. 29 International Business ... (MHIN) will jointly present the 7th Annual MidAmerica ... Wisconsin Technology Council. The conference brings together ... corporate business development executives, angel investors, investment bankers, ...
... Aesthetics, a science-based medical device company dedicated to the development ... has announced the appointment of Gordie Nye as ... founder of Zeltiq Aesthetics, who served as President since September ... the Board of Directors since 2006. Mr. Levinson will ...
Cached Medicine Technology:Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 2Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 3Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 4Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 3
(Date:7/24/2014)... Dr. Henry H. Ting, a nationally recognized ... appointed senior vice president and chief quality officer at ... role, he will oversee the hospital's clinical quality and ... quality initiatives and interprofessional teams at the local, regional ... Door-to-Balloon Alliance, a collaboration of more than 1,000 hospitals ...
(Date:7/24/2014)... [Brown University] The U.S. Preventive Services Task ... for people at high risk for cancer, but ... patients will have positive results on the screening ... testing. Many policymakers have expressed concern that this ... needlessly upset. A new study of National Lung ...
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
(Date:7/24/2014)... 24, 2014 Vulnerable populations such ... households are disproportionately affected by food security, despite ... in the United States, according to a new ... of the Consolidated Appropriations Act, 2014 (P.L. 113-76), ... and Nutrition Service (FNS) to contract with a ...
Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3
... ... No Tobacco Day. According to the World Health Organization, 1 billion people will ... is being given away to inform people about the significant adverse effect tobacco ... Organization,s World No Tobacco Day on May 31. Download the e-book and access ...
... is known about anticancer benefits of supplements, researchers caution , ... vitamins may do nothing to protect men against bladder cancer ... cancer. , In one study examining vitamin use, researchers analyzed ... took part in prostate screenings. , More than 60 ...
... of Alberta,s Faculty of Rehabilitation Medicine have made an ... for spinal-cord injuries. Karim Fouad and David Bennett have ... kick in after injury. To help understand the ... describe the neurons in the spinal cord that control ...
... More than ... International,s three-day eye camp beginning on June 6. Free cataract surgery with lens implant will ... several projects Touching Souls International is providing to the disadvantaged people of Bangladesh during ... ...
... feet first in shallow or unfamiliar waters, experts say , ... the age of 14 are hospitalized each year because of ... in a severe spinal cord injury, researchers say. , To ... to use caution near any body of water and to ...
... Founder ... Published in April 2010, the web store was created to promote healthy living to ... more. Visit the website’s new blog to read-up on product reviews, exercise tips and ... ...
Cached Medicine News:Health News:Celebrate The World Health Organization's World No Tobacco Day, and Get Free eBook - Protect Women from Tobacco Marketing and Smoke 2Health News:Celebrate The World Health Organization's World No Tobacco Day, and Get Free eBook - Protect Women from Tobacco Marketing and Smoke 3Health News:Celebrate The World Health Organization's World No Tobacco Day, and Get Free eBook - Protect Women from Tobacco Marketing and Smoke 4Health News:Celebrate The World Health Organization's World No Tobacco Day, and Get Free eBook - Protect Women from Tobacco Marketing and Smoke 5Health News:Celebrate The World Health Organization's World No Tobacco Day, and Get Free eBook - Protect Women from Tobacco Marketing and Smoke 6Health News:Vitamins Fail to Protect Men Against Bladder Cancer 2Health News:U of A discovery offers promising research for spinal-cord injury treatments 2Health News:Touching Souls International Giving Free Cataract Surgery and Eye Treatment in Bangladesh as Part of Ongoing Program June 6 2Health News:Touching Souls International Giving Free Cataract Surgery and Eye Treatment in Bangladesh as Part of Ongoing Program June 6 3Health News:Touching Souls International Giving Free Cataract Surgery and Eye Treatment in Bangladesh as Part of Ongoing Program June 6 4Health News:Dive Safely -- Or Risk Spinal Cord Damage 2Health News:DRW Weight Loss Debuts Website to Promote Healthy Living and Nutritional Aids 2
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Medicine Products: